Characterization of skin pigment spot apparent in human, comprises comparing expression levels, in skin samples form spot and unwounded adjacent skin, of dermal gene e.g. PLOD2 involved in the remodeling of the extracellular matrix
Method of characterization of skin pigment spot apparent or suspected in a human, comprises comparing expression levels, in skin samples form the spot and unwounded adjacent skin, of at least a dermal gene involved in the remodeling of the extracellular matrix, comprising FRAS1, LEPREL1, MATN2, DST, PLOD2, ITGA2, COL6A3, CRTAP, LAMC1, LAMB3, LAMA3, ITGAV, ITGB1 or ACTNL. Independent claims are included for: (1) a method of evaluating the efficacy of a treatment of skin pigment spots comprising comparing expression levels, in skin samples form the spot after such a spot, before and after treatment, of the dermal gene； (2) an in vitro method for evaluating the efficacy of a treatment of skin pigment spots, comprising comparing, before and after treatment, the level of expression in a representative cellular model of the skin, of the dermal gene or the level of expression or activity of the expression product of the selected gene； (3) cosmetic method of treatment or prevention of skin pigment spot of non-pathological human skin comprising modulating the level of expression or activity of the gene, where the modulation is effected through the use of an antisense molecule, an small interfering (si)RNA, a microRNA or pulsed ultrasound of low intensity； (4) use of a modulator of the expression level or activity of the expression product of the gene, for cosmetic applications in the treatment of non-pathological skin pigment spots, where the modulator is an antisense molecule, siRNA, a microRNA, pioglitazone, miR-183, miR-29b, vitamin K2 menaquinone, beta-aminopropionitrile, low-intensity pulsed ultrasound or vandetanib (ZD6474 5)； and (5) a modulator of the expression level or activity of the expression product of the dermal gene. ACTIVITY : Dermatological. MECHANISM OF ACTION : Gene expression modulator.La présente invention concerne une signature moléculaire des taches pigmentaires cutanées, comprenant les gènes FRAS1, LEPREL1, MATN2, DST, PLOD2, ITGA2, COL6A3, CRTAP, LA
